Cargando…
Regulation of VEGF by mevalonate pathway inhibition in breast cancer
Aminobisphosphonates are used for the treatment of benign and malignant bone disorders. As inhibitors of the mevalonate pathway they exert direct anti-tumor effects in vitro and in preclinical models of bone metastases. Bisphosphonates are thought to have an anti-angiogenic activity as decreased lev...
Autores principales: | Rachner, Tilman D., Göbel, Andy, Junker, Maria, Hötzel, Josefa, Benad-Mehner, Peggy, Hadji, Peyman, Hofbauer, Lorenz C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4723384/ https://www.ncbi.nlm.nih.gov/pubmed/26909280 http://dx.doi.org/10.1016/j.jbo.2013.05.003 |
Ejemplares similares
-
Dickkopf-1 is regulated by the mevalonate pathway in breast cancer
por: Rachner, Tilman D, et al.
Publicado: (2014) -
Zoledronic acid and atorvastatin inhibit αvβ3-mediated adhesion of breast cancer cells
por: Wilke, Maria, et al.
Publicado: (2014) -
Targeting syndecan-1 in breast cancer inhibits osteoclast functions through up-regulation of osteoprotegerin
por: Benad-Mehner, Peggy, et al.
Publicado: (2013) -
Anti-tumor effects of mevalonate pathway inhibition in ovarian cancer
por: Göbel, Andy, et al.
Publicado: (2020) -
Concurrent antitumor and bone-protective effects of everolimus in osteotropic breast cancer
por: Browne, Andrew J., et al.
Publicado: (2017)